• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on Zevra Therapeutics with a new price target

    7/2/25 7:59:19 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVRA alert in real time by email
    H.C. Wainwright initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $26.00
    Get the next $ZVRA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ZVRA

    DatePrice TargetRatingAnalyst
    7/2/2025$26.00Buy
    H.C. Wainwright
    1/8/2025$25.00Overweight
    Cantor Fitzgerald
    10/7/2024$20.00Buy
    Guggenheim
    9/24/2024$17.00Mkt Outperform
    JMP Securities
    9/24/2024$18.00 → $25.00Buy
    Maxim Group
    4/2/2024$12.00 → $18.00Buy
    Maxim Group
    3/12/2024Outperform
    William Blair
    3/17/2023$12.00Buy
    Maxim Group
    More analyst ratings

    $ZVRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Zevra Therapeutics Inc.

      8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      5/29/25 4:42:38 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Zevra Therapeutics Inc.

      DEFA14A - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      5/21/25 4:05:58 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Zevra Therapeutics Inc.

      10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      5/13/25 5:15:59 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

      CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing

      7/28/25 6:00:00 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

      CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced that three posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) and one on OLPRUVA® (sodium phenylbutyrate) are being presented at the 42nd Annual Meeting of the Southeastern Regional Genetics Group (SERGG), taking place July 17-19, 2025, in Asheville, North Carolina. MIPLYFFA is approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA is approved in the U.S. for the treatment of certain patients with urea cycle disorders (UCDs). "We are pleased wi

      7/18/25 7:30:00 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

      CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced the publication of "Long-term Efficacy and Safety of Arimoclomol in Niemann-Pick Disease Type C: Final Results of the Phase 2/3 NPC-002 48-month Open-label Extension Trial" in the peer-reviewed journal, Molecular Genetics and Metabolism (https://doi.org/10.1016/j.ymgme.2025.109189). MIPLYFFA® (arimoclomol) is an approved treatment for Niemann-Pick disease type C (NPC), a neurodegenerative disease caused by lysosomal dysfunction. "NPC is a debilitating and ultimately fata

      7/16/25 7:30:00 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Watton Corey Michael bought $2,352 worth of shares (300 units at $7.84), increasing direct ownership by 20% to 1,800 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      3/31/25 8:05:01 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bode John B bought $79,624 worth of shares (10,000 units at $7.96), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      3/21/25 4:06:49 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Watton Corey Michael bought $3,958 worth of shares (500 units at $7.92), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      10/16/24 4:46:26 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal & Compliance Thompson Rahsaan sold $221,004 worth of shares (24,000 units at $9.21), decreasing direct ownership by 36% to 42,666 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      6/30/25 5:02:34 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal & Compliance Thompson Rahsaan converted options into 66,666 shares (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      6/24/25 5:28:38 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shih Alvin

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      5/30/25 9:41:56 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Zevra Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $26.00

      7/2/25 7:59:19 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Zevra Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00

      1/8/25 8:49:26 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Zevra Therapeutics with a new price target

      Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00

      10/7/24 8:28:23 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Financials

    Live finance-specific insights

    See more
    • Zevra Reports First Quarter 2025 Financial Results and Corporate Update

      Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company's commercial launches and development programs Company to host conference call and webcast today, May 13, 2025, at 4:30 p.m. ET CELEBRATION, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended Mar. 31, 2025. "We are continuing Zevra's transformation into a patient-centric, commercial-

      5/13/25 4:05:00 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

      CELEBRATION, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the first quarter 2025 on Tuesday, May 13, 2025. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at https://investors.zevra.com/. To join via telephone, please use the following dial-in information:

      5/6/25 7:30:00 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

      FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host conference call and webcast today, Mar. 11, 2025, at 4:30 p.m. ET CELEBRATION, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended Dec. 31, 2024. "2024 was a transformational year for Zevra. We emerged as a commercial stage company and are executing on the opportunity to

      3/11/25 4:05:15 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

      Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) ("Zevra," or the "Company"), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspector of Elections following the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"), stockholders have voted to re-elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the

      5/29/25 4:35:32 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics Expands Executive Leadership Team

      Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer. Both Mr. Thompson and Ms. Peters bring deep expertise in building high-performing teams which will be essential to deliver success through the Company's next phase of growth. "We are thrilled to welcome both Rahsaan and Alison to the Zevra team as w

      6/25/24 7:30:00 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

      CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, Zevra's President and Chief Executive Officer, has issued a Letter to Stockholders providing a review of key accomplishments and outlook for 2024. Dear Stockholders, It is hard for me to believe that April 2024 marks six months since the start of my tenure as Zevra's President and Chief Executive Officer in October 2023. From that time, and even prior to my official start date, I began a listening tour, seeking feedback from many of Zevra's stakeholders – stockholders, investors, employees, patie

      4/29/24 7:30:00 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zevra Therapeutics Inc.

      SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

      11/14/24 1:00:16 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

      SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

      11/12/24 5:59:21 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

      SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

      11/4/24 2:15:20 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care